12 analysts have expressed a variety of opinions on Universal Health Servs UHS over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 5 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $248.58, a high estimate of $285.00, and a low estimate of $211.00. This upward trend is evident, with the current average reflecting a 3.65% increase from the previous average price target of $239.83.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Universal Health Servs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $230.00 | $285.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $285.00 | $275.00 |
| Ryan Langston | TD Cowen | Lowers | Buy | $275.00 | $283.00 |
| Frank Morgan | RBC Capital | Lowers | Sector Perform | $211.00 | $222.00 |
| Andrew Mok | Barclays | Raises | Overweight | $271.00 | $256.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $219.00 | $219.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $275.00 | $255.00 |
| Ryan Langston | TD Cowen | Raises | Buy | $283.00 | $220.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $219.00 | $219.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $219.00 | $219.00 |
| Ben Hendrix | RBC Capital | Raises | Sector Perform | $222.00 | $189.00 |
| Michael Ha | Baird | Raises | Outperform | $274.00 | $236.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Universal Health Servs. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Universal Health Servs compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Universal Health Servs's stock. This analysis reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Universal Health Servs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Universal Health Servs analyst ratings.
All You Need to Know About Universal Health Servs
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
Universal Health Servs's Financial Performance
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Universal Health Servs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.23%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Universal Health Servs's net margin is impressive, surpassing industry averages. With a net margin of 6.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Universal Health Servs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.95% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Universal Health Servs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.82% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Universal Health Servs's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
